A transmembrane protein-tyrosine phosphatase receptor type C (CD45) exon A point mutation (77 C to G) is not associated with the development of type 1 diabetes mellitus in a German population

2004 ◽  
Vol 31 (6) ◽  
pp. 245-247 ◽  
Author(s):  
H. Thude ◽  
S. Rosenhahn ◽  
W. Hunger-Dathe ◽  
U.-A. Muller ◽  
D. Barz
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Point Mutation ◽  
Protein Tyrosine Phosphatase ◽  
Transmembrane Protein ◽  
Tyrosine Phosphatase ◽  
German Population ◽  
Type C

scholarly journals Autoimmune thyroid disease and type 1 diabetes mellitus: same pathogenesis; new perspective?

2020 ◽  
Vol 11 ◽  
pp. 204201882095832
Author(s):  
Liyan Li ◽  
Shudong Liu ◽  
Junxia Yu
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Autoimmune Diseases ◽  
Type 1 Diabetes Mellitus ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Current Knowledge ◽  
Tyrosine Phosphatase ◽  
Autoimmune Thyroid

Autoimmune thyroid disease (AITD) and type 1 diabetes mellitus (T1DM) are two common autoimmune diseases that can occur concomitantly. In general, patients with diabetes have a high risk of AITD. It has been proposed that a complex genetic basis together with multiple nongenetic factors make a variable contribution to the pathogenesis of T1DM and AITD. In this paper, we summarize current knowledge in the field regarding potential pathogenic factors of T1DM and AITD, including human leukocyte antigen, autoimmune regulator, lymphoid protein tyrosine phosphatase, forkhead box protein P3, cytotoxic T lymphocyte-associated antigen, infection, vitamin D deficiency, and chemokine (C-X-C motif) ligand. These findings offer an insight into future immunotherapy for autoimmune diseases.

CD45 exon 4 point mutation does not confer susceptibility to type 1 diabetes mellitus or Graves’ disease

2002 ◽  
Vol 29 (1) ◽  
pp. 73-74 ◽  
Author(s):  
J. P. Wood ◽  
K. Bieda ◽  
M. Segni ◽  
J. Herwig ◽  
M. Krause ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Point Mutation ◽  
Graves Disease ◽  
Exon 4

scholarly journals Slowly evolving, immune-mediated diabetes in 14-year-old patient: a case report

2021 ◽  
Vol 24 (1) ◽  
pp. 70-73
Author(s):  
M. R. Ragimov ◽  
D. D. Omelchuk ◽  
L. I. Ibragimova ◽  
O. S. Derevyanko ◽  
T. V. Nikonova
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Insulin Therapy ◽  
Type 1 Diabetes Mellitus ◽  
Autoimmune Diabetes ◽  
Tyrosine Phosphatase ◽  
Acid Decarboxylase ◽  
Latent Autoimmune Diabetes ◽  
Immune Mediated

Slowly developing immune-mediated diabetes, often called latent autoimmune diabetes in adults, is characterized by the presence of autoantibodies (ATs) to glutamic acid decarboxylase (GADA), the patient's age at the onset over 35 years, and the absence of the need for insulin therapy for 6-12 months to 6 years from the moment of diagnosis, according to the WHO classification of 2019, refers to hybrid forms of diabetes mellitus (DM). In this article, we present a case history of slowly developing immune-mediated diabetes in a 14-year-old boy who was transferred from metformin monotherapy and a diet with restriction of digestible carbohydrates to the intensified insulin therapy only 4 years after the onset of diabetes mellitus with a glycated hemoglobin (HbA1c) level of less than 6.5% throughout the disease. As a result of the studies, the patient was found to have a homozygous genotype highly predisposing to the development of Type 1 Diabetes Mellitus (T1DM), as well as increased levels of ATs to GADA and tyrosine phosphatase (IA-2A). The initially preserved level of basal C-peptide and the clinical course of the disease in this patient do not allow us to classify this case as a classic variant of the course of Type 1 Diabetes Mellitus.

Sign in / Sign up

Export Citation Format

Share Document